For the Inventor, By the Inventor

Enter assignee name

Lunella Biotech, Inc.

USPTO Granted Patents = 27

CIPO Patents = 1

EPO Patents = 9

Forward Citations = 2

Loading Chart...

Loading Chart...

7 inventors (with patents filed for the assignee):

Michael P Lisanti (21 out of 23 patents)

Federica Sotgia (21 out of 22 patents)

Federica Sotgia (6 out of 6 patents)

4. Michael P Lisanti (6 out of 6 patents)

5. Jussi Kangasmetsa (3 out of 3 patents)

6. Marco Fiorillo (2 out of 2 patents)

7. Luma G Magalhães (2 out of 2 patents)

8. Federica Sotgia (0 patent)

9. Michael P Lisanti (0 patent)

27 patents: Sort by Forward Citations

1. 12358920 - Substituted pyrrolo[2,3-d]pyrimidines as selective CDK 4/6 inhibitors (2025-07-15),

2. 12319690 - Selective CDK 4/6 inhibitor cancer therapeutics (2025-06-03),

3. 12208111 - Azithromycin and roxithromycin derivtives as senolytic drugs (2025-01-28),

4. 12188936 - Biomarkers and therapeutics for endocrine therapy resistance (2025-01-07),

5. 12006553 - Companion diagnostics for mitochondrial inhibitors (2024-06-11),

6. 11964983 - Selective CDK4/6 inhibitor cancer therapeutics (2024-04-23),

7. 11957700 - Azithromycin and roxithromycin derivatives as senolytic drugs (2024-04-16),

8. 11918597 - Triple combination therapies for anti-aging (2024-03-05),

9. 11865130 - Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells (2024-01-09),

10. 11865124 - Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCS) (2024-01-09),

11. 11738034 - Triphenylphosphonium-derivative compounds for eradicating cancer stem cells (2023-08-29),

12. 11672810 - Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer (2023-06-13),

13. 11667640 - Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells (2023-06-06),

14. 11667639 - Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells (2023-06-06),

15. 11561227 - Anti-mitochondrial inhibitors for oncogenic Ras and Myc (2023-01-24),

Lunella Biotech, Inc. is a leading biotechnology company dedicated to advancing innovative solutions for the healthcare industry. Our team of experts leverages cutting-edge technologies and scientific research to develop breakthrough therapeutics and diagnostic tools. With a strong focus on improving patients' lives, we strive to address unmet medical needs with our novel product portfolio. Visit our website to learn more about our groundbreaking discoveries and the potential they bring to the world of healthcare.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

27 Patents

#58 in

#491 in Canada

#23,272 in the World

Lunella Biotech, Inc.

Forward Citations = 2

7 inventors:

Michael P Lisanti (21 out of 23 patents)

Federica Sotgia (21 out of 22 patents)

Federica Sotgia (6 out of 6 patents)

4. Michael P Lisanti (6 out of 6 patents)

5. Jussi Kangasmetsa (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…